Economic burden of relapsed/refractory chronic lymphocytic leukemia.

被引：2
|
作者：
Guerin, Annie
Ray, Saurabh
Gauthier, Genevieve
Hsu, Ling-I
Zhdanava, Maryia
Heroux, Julie
Wu, Eric Qiong
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] AbbVie, N Chicago, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e18065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18065
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The economic burden of chronic lymphocytic leukemia in the United States
    Morlock, R. J.
    Atkinson, M. J.
    Pollock, M. R.
    Matthies, A.
    VALUE IN HEALTH, 2008, 11 (03) : A66 - A66
  • [42] Cost of illness and economic burden of chronic lymphocytic leukemia
    Carl Rudolf Blankart
    Taika Koch
    Roland Linder
    Frank Verheyen
    Jonas Schreyögg
    Tom Stargardt
    Orphanet Journal of Rare Diseases, 8
  • [43] Cost of illness and economic burden of chronic lymphocytic leukemia
    Blankart, Carl Rudolf
    Koch, Taika
    Linder, Roland
    Verheyen, Frank
    Schreyoegg, Jonas
    Stargardt, Tom
    ORPHANET JOURNAL OF RARE DISEASES, 2013, 8
  • [44] Fludarabine as single therapy for advanced stage of refractory chronic lymphocytic leukemia.
    Giraldo, P
    Palomera, L
    Mayayo, P
    Moneva, JJ
    Diego, P
    Pardo, M
    Rabasa, P
    Rubio-Félix, D
    BLOOD, 1998, 92 (10) : 276B - 276B
  • [45] Phase I study of combination rituximab with apolizumab in relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia.
    Dunleavy, K
    White, T
    Grant, N
    Shovlin, M
    Stetler-Stevenson, M
    Pittaluga, S
    Jaffe, ES
    Marti, G
    Janik, J
    Wilson, WH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 586S - 586S
  • [46] Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia.
    Maddocks, Kami
    Lapalombella, Rosa
    Blum, Kristie A.
    Blum, William
    Fischer, Beth B.
    Muthusamy, Natarajan
    Moran, Mollie E.
    Holtzapfel, Donna
    Byrd, John C.
    Johnson, Amy J.
    Andritsos, Leslie
    BLOOD, 2009, 114 (22) : 1339 - 1339
  • [47] A phase II, open label study of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
    Castro, Januario E.
    Olivier, Loria J.
    Robier, Aguillon A.
    Danelle, James
    Carlos, Suarez J.
    Bi-Ying, Yeh
    Thomas, Kipps J.
    BLOOD, 2006, 108 (11) : 803A - 803A
  • [48] Fostamatinib Inhibits BCR Signaling, and Reduces Tumor Cell Activation and Proliferation in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia.
    Herman, Sarah E. M.
    Barr, Paul M.
    McAuley, Erin M.
    Liu, Delong
    Friedberg, Jonathan W.
    Wiestner, Adrian
    BLOOD, 2012, 120 (21)
  • [49] Optimizing Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Mato, Anthony
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (5.5): : 581 - 583
  • [50] Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography
    Benedetti, Edoardo
    Barate, Claudia
    Bruno, Benedetto
    Bramanti, Emilia
    Ghia, Paolo
    Scarfo, Lydia
    Morganti, Riccardo
    Ricchiuto, Vittorio
    Galimberti, Sara
    LEUKEMIA RESEARCH, 2021, 100
12345